 | | | Vol. 12.32 – 17 August, 2021 |
|
|
|
| Investigators determined that ex-vivo-cultured mouse and human HSCs rapidly increased protein synthesis. This challenge to HSC proteostasis was associated with nuclear accumulation of Hsf1, and deletion of Hsf1 impaired HSC maintenance ex vivo.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that sympathetic nerve-derived dopamine directly controlled hematopoietic stem and progenitor cell behavior through D2-subfamily dopamine receptors.
[Blood] |
|
|
|
| Scientists showed that human T cells engineered to express an mLPA-specific TCR, targeted diverse CD1c-expressing leukemia blasts in vitro and significantly delayed the progression of three models of leukemia xenograft in NSG mice, an effect that was boosted by mLPA-cellular immunization.
[Nature Communications] |
|
|
|
| Exploiting the mutational footprint of some chemotherapies, researchers explored their influence on the evolution of hematopoietic cells.
[Nature Communications] |
|
|
|
| Using a sphingolipid network focused CRISPR/Cas9 library screen, scientists identified an endoplasmic reticulum enzyme, 3-Ketodihydrosphingosine reductase, to be essential for leukemia cell maintenance.
[Leukemia] |
|
|
|
| The increased stemness of acute myeloid leukemia (AML) cells promoted by regulatory T cells (Tregs) was verified in vitro and in vivo, and researchers found that blocking the interaction between Tregs and AML cells may be a new approach to target leukemia stem cells in AML treatment.
[Leukemia] |
|
|
|
| Investigators showed that acute myeloid leukemia cells secreted the stem cell growth factor R-spondin 2 (RSPO2) to promote their self-renewal and prevent cell differentiation.
[Cell Reports] |
|
|
|
| The authors found that interleukin-10 receptor (IL-10R) was overexpressed in most acute myeloid luekemia cells, and played an important role in promoting the stemness of leukemia cells.
[Blood Cancer Journal] |
|
|
|
| Using in vitro models of JAK2r B-ALL, JAK2 p.G993A conferred resistance to six type-I JAK inhibitors and the type-II JAK inhibitor, CHZ-868.
[npj Precision Oncology] |
|
|
|
| Patients’ gene expression profile from seven GEO databases was normalized after removing the batch effect. Tumor immune microenvironment (TIME) cell components were explored through Xcell tools and then hierarchically clustered to establish TIME classification.
[BMC Medicine] |
|
|
|
| Investigators suggested that the main role of Bim in hematopoietic cells was the neutralization of Mcl-1, identified a number of likely molecular events during the maintenance of survival and the induction of apoptosis in mouse hematopoietic progenitor cells, and provided data on the regulation of expression and importance of these proteins during differentiation along the B cell lineage.
[Cell Death & Disease] |
| |
|
|
| This Phase I-II study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). BV and Nivo with staggered or concurrent dosing were active and well tolerated when used as first salvage therapy in patients with r/r cHL.
[Blood] |
|
|
|
| Scientists studied iron metabolism in patients with acute myeloid leukemia at diagnosis and explored the mechanisms involved using the syngeneic MLL-AF9–induced AML mouse model.
[Blood Advances] |
|
|
|
|
| The authors explore the potential of transplanting exogenous umbilical cord blood cells and mobilizing host resident stem cells in vascular dementia and aging.
[Stem Cell Reviews and Reports] |
|
|
|
| The association between hematopoietic stem-cell transplantation and early- and late-onset cardiotoxicity remains controversial as these cardiac complications, including acute heart failure and arrhythmia, such as atrial fibrillation, can occasionally be lethal.
[Bone Marrow Transplantation] |
|
|
|
|
| IN8bio, Inc. announced completion of dosing of the first patient cohort in a Phase I clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant.
[IN8bio, Inc.] |
|
|
|
| Fulcrum Therapeutics, Inc. announced positive interim results from the ongoing single- and multiple-ascending dose Phase I trial with FTX-6058 in healthy adult volunteers.
[Fulcrum Therapeutics, Inc.] |
|
|
|
| Allogene Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic CAR T therapies for cancer, announced that the US FDA has granted ODD to ALLO-715 for the treatment of MM.
[Allogene Therapeutics, Inc.] |
|
|
|
| Medexus Pharmaceuticals, Inc. announced that is has completed enrollment in its Phase IV Clinical Trial of IXINITY®, targeting label expansion for pediatric hemophilia B patients.
[Medexus Pharmaceuticals, Inc.] |
|
|
|
|
| October 12 – 14, 2021
Carlsbad, California, United States and Virtual |
|
|
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | University Of Wisconsin–Madison – Madison, Wisconsin, United States |
|
|
|
| | Queen’s University Belfast – Belfast, Northern Ireland, United Kingdom |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | The Scripps Research Institute – La Jolla, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
